Also included are some observations on a positive contribution to reduced length of stay for people with diabetes in hospital, and low incidences of prescription and management errors in the first National Diabetes Inpatient Audit in 2009. Specifically between 2005 and 2007 the average length of stay in days for all patients whose diagnosis included diabetes fell from 9.39

to 3.76 days despite the total number of patients increasing from 507 to 633 over the same quarter each year. The inpatient team provided almost 1000 visits to patients with diabetes in the first six months of each year 2008 and 2009, and at the first National Diabetes Inpatient Audit had only 5% prescription errors and 3% management errors (versus 19% and 14% respectively nationally) with 100% appropriate blood glucose testing. We suggest that a dedicated inpatient diabetes care team raises the quality of care

for patients and enhances 17-AAG datasheet patient and professional education; we also suggest that audit standards should be developed for inpatient Selleckchem Trametinib diabetes care and assessed in future national audits. Copyright © 2011 John Wiley & Sons. “
“Liraglutide is not predominantly eliminated by renal excretion. We assessed its safety and efficacy among patients with mild and moderate renal impairment. Patients from a nationwide audit of liraglutide (1.2mg) use were divided according to pre-treatment renal function calculated by the Cockcroft-Gault formula. Adverse events, liraglutide discontinuation and changes in HbA1c, weight, systolic blood pressure and serum creatinine were compared between groups of different pre-treatment renal function. As compared with patients with normal renal function (n=1446), patients with mild renal Methocarbamol impairment (n=288) and moderate renal impairment (n=57) were equally likely to report gastrointestinal side effects (adjusted OR 1.11 [95% CI 0.80–1.54] and 0.67 [95% CI 0.31–1.48]), respectively, but more frequently stopped liraglutide due to gastrointestinal side effects (adjusted OR 2.32 [95% CI 1.45–3.74] and 2.37 [95% CI 0.97–5.81]), respectively. Minor hypoglycaemia and

acute renal failure were uncommonly reported and were not more frequent among patients with renal impairment. Patients remaining on treatment in all three groups achieved significant HbA1c and weight reduction at six months (between 11 to 12mmol/mol [1.0 to 1.1%] and -3.6 to -3.8kg). No effect of renal function was seen influencing the degree of HbA1c and weight reduction. Liraglutide treatment was associated with a small reduction in serum creatinine among patients with renal impairment. We concluded that liraglutide was safe, efficacious but more frequently discontinued among patients with mild renal impairment. More data are needed to establish its safety among patients with moderate or more significant renal impairment. Copyright © 2013 John Wiley & Sons.